Simvastatin induces cell cycle arrest and inhibits proliferation of bladder cancer cells via PPARγ signalling pathway
Simvastatin, a drug for heart disease by lowering cholesterol, also slows bladder cancer (BLCA) growth. It stops BLCA cells from multiplying by activating PPARγ, a fatty aicd/lipid metabolism pathway. This effect can be reversed with PPARγ inhibitors.